Biogen's experimental MS drug performs well in late-stage trial

01/25/2013 | Bloomberg Businessweek · Reuters

Biogen Idec's injectable multiple sclerosis treatment Peg-Avonex, or peginterferon beta-1a, met the goals of a Phase III trial by reducing patients' relapse rate by 36% when given every two weeks and by 28% on four-week schedule compared with placebo. The drug was also safe and well-tolerated. Biogen plans to submit the drug for approval in the U.S. and Europe this year.

View Full Article in:

Bloomberg Businessweek · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN